Previous studies found that bone marrow (BM) allografts from DLA-identical littermates resulted in survival of two thirds of recipient dogs after otherwise lethal doses of 450 t o 600 cGy of total body irradiation (TBI) because of successful allografts or autologous recovery after rejection of the allografts. The current study asked whether survival could be further improved by treating allograft recipients with recombinant canine granulocyte colony-stimulating factor (G-CSF), stem cell factor (SCF), or G-CSF/SCF. Of 21 dogs, 14 (67%) receiving allografts but no growth factors survived, 10 with successful allografts (including 5 mixed chimeras) and 4 with autologous recovery; whereas 7 animals died, 5 from infections during BM aplasia and 2 from acute graft-versus-host disease. By comparison, 30 of 34 dogs (88%) receiving hematopoietic growth factors in addition to the BM graft survived, 17 with successful allografts (including 10 mixed chimeras) and 13 with autologous recovery; whereas 4 died, all with WO APPROACHES HAVE been used to treat victims of radiation accidents who may have been exposed to a broad range of irradiation exposures. One has involved hematopoietic growth factor^,"^ and the other has involved bone marrow (BM) tran~plantation.~ We have examined both approaches in a canine model. Results of these studies5" as well as those of MacVittie et a18 showed that the usefulness of hematopoietic growth factors in improving survival of radiation accident victims was limited. Rescue from BM death was possible with canine recombinant granulocyte colony-stimulating factor (G-CSF) or stem cell factor (SCF or c-kit ligand) after 400 cGy total body irradiation (TBI) (80% survival), but was less so after 500 cGy TB1 (20% survival), and was not at all possible after 600 cGy TBI.5" Canine recombinant granulocyte-macrophage-CSF (GM-CSF) was not useful in this model of radiation injury to BM, with only 1 of 10 dogs surviving after 400 cGy TBI.9 By comparison, treatment of irradiated dogs by DLA-identical BM transplantation improved survival over a much broader range of infection related t o BM aplasia after rejection of the allograft. Survival was similar for recipients of G-CSF, SCF, or the combination of G-CSF and SCF. Logistic regression analyses, which accounted for possible effects of TB1 dose, showed a trend for improved survival in dogs receiving growth factors ( P = .09), no change in allogeneic engraftment ( P = .74), and a slight increase in autologous recovery (P = ,221. In agreement with previous data, we found that grafts of BM from DLA-identical littermates improved survival of recipient dogs exposed to low but otherwise lethal doses of TBI. A further improvement in survival could be achieved by additional treatment with G-CSF, SCF, or G-CSF/SCF. Results suggest that treatment by hematopoietic growth factors along with BM grafts should be considered for victims of radiation accidents. radiation exposures (450 to more than 1100 cGy TBI).'""' Depending on the TB1 dose administered, BM-grafted dogs survived either with successful and complete allografts, with recovery of mixed donor and host hematopoiesis, or, after rejection of the allograft, with complete autologous BM recovery. In the latter setting, survival was likely aided by the extended hematopoietic support provided by the transient allograft. However, at the lower TB1 exposures studied (450 to 800 cGy), approximately one third of the dogs died, usually from infections during the period of transition between rejection of the BM allograft and recovery of autologous BM function.
In the present study, we chose two doses of TBI, 450 and 600 cGy, and asked whether survival of dogs could be further improved if DLA-identical BM transplants were combined with treatment by canine recombinant hematopoietic growth factors G-CSF, SCF, or a combination of the two. We hypothesized that survival might improve if growth factors enhanced allogeneic BM engraftment, autologous recovery, or both and reduced the risk of infection caused by granulocytopenia. We found that growth factors increased survival.
MATERIALS AND METHODS
Litters of beagles, Walker hounds, harriers, foxhounds, and pit bullbeagle crossbreeds were either raised at the Fred Hutchinson Cancer Research Center (Seattle, WA) or purchased from commercial kennels in the state of Washington. The dogs weighed from 5.6 to 22.3 kg (median, 9.5 kg) and were between 5.5 and 20.5 months old (median, 7.0 months old). They were observed for disease for at least 2 months before entering the study. All were immunized for parvovirus, distemper, leptospirosis, and hepatitis. Tables 1 and 2 ) have been previously reported.".'* They are included here for purposes of comparing transplant outcomes with and without growth factors. Donorhecipient pairs were of opposite sex in all but 2 cases to permit cytogenetic evaluation of BM and PB cells for chimerism after transplantation.I6 In addition, in 17 pairs, a polymerase chain reaction (PCR)-based assay for polymorphic (CA), repeats in DNA from BM and PB mononuclear cells was used to assess the success of the allograft (Ostrander et all7 and Yu et all7").
BM for transplant was aspirated under general anesthesia through needles inserted into humeri and femora as described.18 Recipients were administered TB1 from two opposing @'CO sources as described in
The midplane dose rate was 7 cGy per minute. Total doses of TB1 administered were either 450 cGy or 600 cGy.
Recipients were administered between 1.5 and 4.7 X 10' nucleated BM cells (median, 3.9 X lo8) per kilogram by intravenous infusion within 4 hours of TBI. The day of BM infusion was designated as day 0. Dogs did not receive postgrafting immunosuppression. Postgrafting care has been described.",'* Briefly, all dogs received prophylactic systemic antibiotics twice daily (usually ceftazidime unless sensitivity tests indicated otherwise). Systemic antibiotics were begun on the day of TBI, and they were continued until the white blood cell count reached l,OoO/pL after the postirradiation nadir. Beginning on day 5 before T B 1 until white blood cell count recovery, dogs also received twice daily oral nonabsorable antibiotics, neomycin sulfate, and polymyxin sulfate. Parenteral fluids and electrolytes were administered as indicated. In addition, dogs received red blood cell and platelet support based on the results of their daily blood counts. All transfusions were irradiated in vitro with 2,000 cGy from a cesium source.
Six groups of recipients were studied, as shown in Tables 1 and  2 BM engraftment was assessed by sustained increases in granulocyte (Fig 1) and platelet counts after the postirradiation nadir, by histologic features of the BM from biopsy or autopsy specimens, by documentation of cells with donor karyotype16 or with donor (CA), repeat polymorphismsz0 (Fig 2) in specimens from PB and BM, and by development of graft-versus-host disease (GVHD). Graft rejection was defined as failure of sustained recovery of granulocyte (Fig l) or platelet counts of donor origin after the postirradiation nadir, along with extreme BM hypocellularity at autopsy, or decreasing counts after initial engraftment followed by reappearance of cells with host karyotype or host (CA). repeat polymorphisms, and absence of clinical and histologic features of GVHD.
In 17 cases, the two marker methods, cytogenetics and (CA), repeat polymorphisms, were used on the same dogs. In 11 instances, results were identical. In 6 instances, discrepancies were noted with cytogenetics showing either all donor (n = 3) or all host (n = 2) cells and (CA), dinucleotide repeats showing mixtures of host and donor cells in 5 cases and the inverse finding in 1 case. These discrepancies may be because of the differences in cells examined by the two techniques, with cytogenetics restricted to karyotypes from dividing cells and with the PCR-based technique to detect (CA),, dinucleotide repeats looking at DNA from both dividing and nondividing cells. In the latter case, the existence of long-lived lymphocytes of host or donor type may lead to the detection of a small host or donor band, consistent with mixed chimerism. The PCR technique is sensitive enough to detect as little as 2.5% to 97.5% mixtures. For the purposes of this study, mixed chimerism was assumed if cytogenetics, dinucleotide (CA). repeat markers, or both showed mixtures of host and donor hematopoietic cells. Table 1 and Fig 3 summarize the results in dogs conditioned with 450 cGy of TBI. Of the 10 dogs in group 1, 2 receiving no growth factors failed to show recovery of PB cell counts after the postirradiation nadir and died on day 20 from infection or pneumonia, respectively, with hypoplastic BM. One additional dog showed extremely slow hematopoietic recovery and died with pneumonia on day 30, also with a hypoplastic BM. Three dogs showed increasing granulocyte and platelet counts. Beginning by day 19, counts decreased and reached very low levels by day 25. All 3 showed subsequent complete autologous recovery of their PB counts. In 1 of these, cytogenetic data confirmed the initial donor engraftment followed later on by the finding of cells of host karyotype. Four dogs showed persistent donor engraftment (including 2 mixed chimeras). Of the 4 , 2 developed transient GVHD that did not require treatment.
RESULTS
Of the 7 dogs receiving G-CSF after transplant, 1 failed to show recovery of PB counts after the postirradiation nadir and died on day 20 with pneumonia. BM cells found on day 14 showed only the host karyotype. At autopsy the BM was severely hypoplastic. In the other 6 dogs, early cytogenetics showed donor hematopoietic cells, and this persisted in 2 during the period of study (including one mixed chimera), whereas in 4 of the dogs ultimately all cells studied showed the host karyotype, a finding that was consistent with initial allogeneic engraftment followed by rejection and then by recovery of host hematopoietic cells. No GVHD was observed in the 2 dogs with persisting BM allografts.
Of the 7 dogs receiving SCF after transplant, 1 died early on day 20 with pneumonia without evidence of engraftment and with a severely hypoplastic BM at autopsy. Three showed persistent mixtures of donor and host hematopoietic cells without GVHD, whereas 3 dogs rejected the allogeneic BM and showed complete autologous recovery.
All of the 8 dogs receiving both G-CSF and SCF after transplant showed prompt initial hematopoietic recovery. Donor-type hematopoiesis persisted in 1, mixed hematopoietic chimerism in 3, and complete host-type recovery was observed in 4 of the dogs. None of the dogs with allografts had GVHD. hyperacute GVHD and infectious complications. Of the remaining 7 dogs, 1 showed complete autologous recovery. 3 remained mixed hematopoietic chimeras without GVHD, and 3 showed all donor-type hematopoiesis without GVHD. One additional dog was treated in group 5 and survived. but the type of recovery could not be evaluated because of lack of appropriate blood genetic markers.
Of the 12 dogs receiving G-CSF after transplant. 2 died early on days 14 and 15, respectively. with septicemia and aplastic BMs. Of the 10 surviving dogs, a l l but 1 had evidence of initial allogeneic hematopoietic engraftment. Of these 9. 2 ultimately rejected their grafts, and only host cells were found by karyotyping. Among the other 7. S showed all donor-type engraftment, whereas 2 remained mixed hematopoietic chimeras. None of the 7 dogs with persisting allogeneic cells had GVHD. Table 3 summarizes the overall results in the dogs receiving 450 and 600 cGy of TBI. respectivcly, with or without subsequent treatment by hematopoietic growth factors. Dogs not treated with growth factors had an overall early mortality of 33%. an allogeneic engraftment rate (including mixed chimerism) of 48%, and an autologous recovery rate of 19%. By comparison, those receiving growth factors had an early mortality of 12%. an allogeneic engraftment rate of 5076, and an incidence of autologous recovery of 38%. Logistic regression analysis accounting for the differing TB1 doses indicated that dogs receiving growth factor had improved chances of overall survival ( P = .09).
Although most dogs were observed for prolonged periods of time. some were killed early. between days 36 and h9 after transplant. because hematopoiesis was all of either host or donor type. In this and previous studies.""" late reversals from host to donor type hematopoiesis and vice versa have dogs giving examples of persistent mixed chimerism, initial been the exception, and the development of late BM aplasia mixed chimerism followed by complete allogeneic enhas never been observed. Table 4 shows the results of dinugraftment, or initial mixed chimerism followed by autolocleotide (CA). marker and cytogenetic studies in 4 of the gous recovery. For
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In 3 of the 17 dogs, in which both tests of chimerism were used, results obtained with dinucleotide (CA), markers in peripheral mononuclear cells differed from those obtained with cytogenetics in that the former showed mixed chimerism and the latter showed host-type cells. This finding may be related to differences in cells analyzed by the two techniques, ie, all nucleated cells by (CA), markers versus only dividing cells by cytogenetics. For example, nondividing long-lived lymphocytes would be detected by the (CA). marker test but not by cytogenetics.
DISCUSSION
Results in this canine model were obtained with TB1 doses of 450 and 600 cGy, which are uniformly lethal in the absence of treatment by either hematopoietic growth factors or infusion of BM.' The doses were chosen to approximate those that may be encountered for human nuclear accident victims. However, it must be remembered that current results have been obtained with gamma radiation, whereas nuclear accidents usually involve mixed gamma-fission neutron radiation with fission neutrons thought to have contributed between one quarter to one third of the total exposure." Additionally, there are other variables that may affect the outcome in human accident victims. These may include thermal radiation injury, variable dose rates, or prolonged radiation exposures caused by ingestion of radioactive isotopes. Nevertheless, within these limitations, the current and previous results in the canine model have clinical relevance. In fact, as early as 1959, Mathe et alZ2 hypothesized that transiently engrafting human BM allografts could be used to protect patients from the sequelae of exposure to a radiation accident." The canine data show that BM grafts from DLA-identical littermates are useful in extending the survival of dogs exposed to otherwise lethal doses of TBI. In this and previous studies,""' two thirds of dogs survived. Survivors included 86% of those dogs that had successful allografts and 57% of those that rejected the allograft. By comparison, treatment of dogs exposed to 400, 500, and 600 cGy of TBI, respectively, with hematopoietic growth factors but with no BM grafts resulted in endogenous BM recovery and survival in a smaller percentage of In fact, at 600 cGy, no dogs survived with treatment by G-CSF, SCF, or a combination thereof.
The current study in which DLA-identical BM grafts were combined with treatment by hematopoietic growth factors after transplantation was performed under the assumption that the incidence of sustained allogeneic engraftment and/or of autologous recovery would increase, with both of these hypothetical events increasing survival because of a shortened period of granulocytopenia. We found that the allogeneic engraftment rates were only slightly increased to 45% (450 cGy) and 58% (600 cGy) in dogs receiving growth factors compared with 40% (450 cGy) and 55% (600 cGy) among controls. However, there was some evidence for an increase in the incidence of autologous BM recovery from 30% to 45% at 450 cGy and from 9% to 25% at 600 cGy, which contributed to a strongly suggestive increase in survival from 70% to 91% at 450 cGy and from 64% to 83% at 600 cGy. Clearly, hematopoietic stimulation by G-CSF and SCF did not alter the risk of allograft rejection in this model. Whether this finding might lessen concerns for increased graft rejection in other transplant settings, eg, unrelated BM grafts after high-dose TBI, remains conjectural. Although not significantly affecting the rate of allogeneic engraftment, G-CSF and SCF increased survival among dogs that rejected the allograft by promoting endogenous BM recovery under the protection of the cellular support provided by the transient allograft. Also, both in the preceding'""2 and in the present studies, there was very little evidence for acute or chronic GVHD in dogs with sustained allografts, a finding that may be related to a prolonged state of mixed host/donor chimerism known to facilitate graft-host tolerance in studies in mice.2' Only 2 of the 26 current dogs with allografts died from complications associated with acute GVHD, and no dog developed chronic GVHD. A lessened incidence of acute GVHD was also reported in patients with aplastic anemia who received BM grafts from HLA-identical siblings and who showed prolonged mixed hematologic chimerism after tran~plant.'~ Studies similar to those reported here were performed by Blazar and colleagues in The major differences from the current study were that these investigators used a histoincompatible donorlrecipient combination with transplants from BALB/c mice into C57BL/6 recipients (H-2d-tH2h), that grafts were T-cell-depleted, and that recipients were conditioned with a higher dose of TB1 (7.5 Cy) delivered at a higher dose rate (45 cGy/min). They found survival advantages when using human recombinant GM-CSF,'' human recombinant G-CSF,26 as well as interleukin-la (1L-la)." In the case of G-CSF and GM-CSF, even though there was a survival advantage, this was not becuase of an increase in the rate of allogeneic engraftment. In fact, with GM-CSF, the rate of allogeneic engraftment decreased compared with that observed in controls. In the case of IL-la, improved survival was the result of an increase in the rate of allogeneic engraftment. The investigators noted an interactive effect with regard to allogeneic engraftment when IL-1 a was combined with GM-CSF.
In conclusion, consistent with previous results from this""' and other laboratories,**"" DLA-identical littermate BM grafts improved survival of dogs exposed to otherwise lethal doses of TBI, with survivors showing either successful allografts or endogenous BM recovery after rejection of the transient graft. Nevertheless, one third of dogs died early from infections. When BM allografts were combined with treatment by hematopoietic growth factors, recombinant canine G-CSF, SCF, or G-CSF/SCF, survival was improved. Most likely, this improvement was because of higher overall levels in granulocyte counts among dogs receiving growth factor treatment resulting in a lessened incidence of fatal infections. Figure I shows the granulocyte nadir in a G-CSF-treated dog at about 2,00O/pL versus a mean count of about 400/pL in 5 dogs not receiving a cytokine. Equally important, most cytokine-treated dogs did not experience the second granulocyte nadir that was observed in the noncyto- 
